candesartan cilexetil has been researched along with olmesartan medoxomil in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Arakawa, N; Fujimori, I; Inoue, T; Nakamura, H; Shimakawa, E; Shimizu, Y; Toyoshi, T; Yokoyama, T; Yoshigae, Y | 1 |
| Arakawa, K; Brunner, HR | 1 |
| Furukawa, T; Hatsuno, T; Isshiki, T; Nagaoka, K; Sagawa, T; Ueno, Y; Watari, Y; Yamakawa, T | 1 |
| Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J | 1 |
| Ishizuka, T; Izumi, T; Murayama, N; Yoshigae, Y | 1 |
| Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y | 1 |
| Asai, S; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y; Yada, Y | 1 |
1 trial(s) available for candesartan cilexetil and olmesartan medoxomil
| Article | Year |
|---|---|
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Time Factors; Treatment Outcome | 2006 |
8 other study(ies) available for candesartan cilexetil and olmesartan medoxomil
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Glycated Hemoglobin; Heart Rate; Hypertension; Hypoxia; Imidazoles; Male; Olmesartan Medoxomil; Oxygen; Rats; Rats, Inbred SHR; Retinal Neovascularization; Tetrazoles | 2005 |
Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2009 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Biphenyl Compounds; Digoxin; Fluoresceins; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Olmesartan Medoxomil; Tetrazoles; Thiophenes | 2010 |
Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Carboxylesterase; Carboxylic Ester Hydrolases; Dogs; Female; Humans; Hydrolases; Hydrolysis; Imidazoles; Macaca fascicularis; Male; Mice; Olmesartan Medoxomil; Oxadiazoles; Prodrugs; Rats; Rats, Sprague-Dawley; Tetrazoles; Tissue Distribution | 2013 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2013 |
Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Topics: Aged; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Aspartate Aminotransferases; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Blood Urea Nitrogen; Cohort Studies; Creatinine; Dihydropyridines; Drug Combinations; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Potassium; Propensity Score; Retrospective Studies; Sodium; Tetrazoles; Uric Acid | 2016 |